Developer Dmitry Baskin Completes Boston's First Passive Houses therealdeal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from therealdeal.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Renovia Inc. (Renovia), a developer of non-surgical treatments for female pelvic floor disorders and an advocate for women s health, announced.
Novel Preference Studies and their Applications in the Pharmaceutical, Medical Device and Diagnostics Industries, Upcoming Webinar Hosted by Xtalks
Share Article
In this free webinar, the featured speaker will consider the use cases and applications of patient and provider preference studies involving pharmaceutical, medical device and diagnostic products and identify the appropriate timing in the product lifecycle for these studies. Attendees will understand the different types of preference studies that can be conducted in healthcare research.
Companies that develop products that address patient and provider perspectives in the product development stage are more likely to deliver products that satisfy important unmet needs in the complex and dynamic healthcare market, which increases the odds of product success.
Artificial intelligence was predictive of care strategies for patients with diabetic kidney disease, a new study found.
Test results from the KidneyIntelX diagnostic tool were significantly tied to how a primary care physician tailored a patient s treatment strategy, reported Manasi Datar, PhD, of Boston Healthcare Associates in Massachusetts, and colleagues.
Specifically, having a patient with a high-risk KidneyIntelX result was associated with a 64% (OR 1.64, 95% CI 1.29-2.08) higher odds of a primary care physician prescribing an SGLT-2 inhibitor with a diabetic kidney disease indication, such as canagliflozin (Invokana) which gained this expanded indication in September 2019.
The prognostic test identifying a patient as high risk was also tied to a 49% higher odds of the primary care physician increasing the patient s angiotensin II receptor blocker (ARB) dose (OR 1.49, 95% CI1.17-1.89) compared with patients who did not undergo this test.
Share this article
Share this article
NEW YORK, April 7, 2021 /PRNewswire/ Today, before the National Kidney Foundation s 2021 Spring Clinicals Meetings of thousands of kidney health professionals, hundreds of studies from the last year were presented including three studies considered late-breaking research papers.
The presentations were made at the virtual presentation at the annual Spring Clinical Meetings, which was held virtually for the second year due to COVID-19 restriction. The event is a chance for investigators to share their findings with professionals who attend the conference, which is one of the most respected gatherings of kidney professionals in the United States.